Please do not leave this page until complete. This can take a few moments.
New Haven-based Osmol Therapeutics announced Tuesday it had closed the first $5.2 million tranche of a $7.5 million Series A-1 financing round toward development of its treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Koax Investment Partners, a fund formed by the founders of Biohaven Pharmaceuticals, led the round.
Osmol’s lead drug candidate, OSM-0205, is based on research in neuronal calcium sensor-1 by Barbara Ehrlich, a professor of pharmacology at Yale and Osmol’s Chief Scientific Advisor. The technology was licensed from Yale.
The drug is designed to prevent the off-target calcium surge caused by taxanes, a common chemotherapy drug, and other cancer treatments associated with peripheral neuropathy, or nerve damage.
“We believe that OSM-0205 has the potential to address the critical need for a therapy that can prevent CIPN, a condition that can be devastating for cancer patients,” said Dr. Robert Berman, executive chairman of Osmol. Up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN.
There are currently no FDA-approved therapies for the prevention or treatment of CIPN, according to a company statement.
Osmol also plans to explore use of its drug for chemotherapy-induced cognitive impairment, also known as “chemobrain.”
“OSM-0205 has the potential to provide similar protection to the central nervous system as these chemotherapy treatments cross the blood-brain barrier,” Berman said.
Contact Liese Klein at lklein@newhavenbiz.com.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering vital marketplace content and context to senior decision-makers throughout Connecticut ...
All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments